Merck's Keytruda fails triple negative breast cancer pivotal study
Months after the FDA sanctioned the approval of Roche’s runner up checkpoint inhibitor Tecentriq in combination with Celgene’s Abraxane for treatment naive patients with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
